import { Grid } from "@mui/material"

export const PDFDownload = () => (

    <Grid style={{ whiteSpace: 'nowrap', padding: '0px 20px' }}>
        <p className="primary-color font-source-sans-pro fw-700 fs-24">
            Capso(88763249)
        </p>
        <div style={{ padding: '0px 10px' }} >
            <p className="font-source-sans-pro fs-16 fw-500">
                R&D Report for financial period ending 30 June 2018
            </p>
            <p>Company contact: Andrew Johnson , Project Manager</p>
            <p className="primary-color font-source-sans-pro">Claim period</p>
            <p className="fs-18 font-source-sans-pro fw-400">
                Capso Therapeutics (the company) has compiled this document
                to support its claim for R&D tax <br /> relief for accounting
                period 29 June 2017 to 30 June 2018.
            </p>
            <p className="primary-color font-source-sans-pro">Group status</p>
            <p className="font-source-sans-pro">
                At the end of the claim period, Ansai Limited was not part
                of a group, and had no external  shareholders  <br /> It had no
                significant shareholdings.
            </p>
            <p className="primary-color font-source-sans-pro">Scheme eligibility</p>
            <p className="fs-18 font-source-sans-pro fw-400">
                Capso Therapeutics had two staff. Turnover to 30 June 2018
                was £84,400 and total balance sheet <br /> assets were £40,047. The
                company was not part of a group and had no significan
                hareholders or shares  <br />in other companies. Ansai Limited. is
                therefore  considered to be a SME for the purposes of R&D tax  <br />
                relief.
            </p>
            <p className="primary-color font-source-sans-pro">Commercial goals</p>
            <p className="fs-18 font-source-sans-pro fw-400">
                During the claim period, the company undertook commercial
                work, relevant to its current  trade , to <br /> diversify into new
                markets reverse engineer its competitors’ products, develop
                one or more new <br /> products  or services, and improve one or
                more products in a measurable and objective way This <br />
                commercial work underpinned the company's need   to carry out
                research and development.
            </p>
            <p className="primary-color font-source-sans-pro">Technical objectives</p>
            <p className="fs-18 font-source-sans-pro fw-400">
                Working in the areas of computer science, software
                development, and web application development <br /> Capso
                Therapeutics assessed its technical projects against the
                guidance of  CIRD 81900 Paragraph <br /> 9a-d. The extent of its
                activities are summarised in the chart below.
            </p>
            <p className="primary-color font-source-sans-pro fs-16 fw-600">
                Definitions of CIRD 81900 Para 9a-d
            </p>
            <p className="font-source-sans-pro">
                9a: Extending overall knowledge or capability in a field of
                technology.
            </p>
            <p className="font-source-sans-pro">
                9b: Wrapping new technical knowledge or capability within a
                product, process, device, material or service.
            </p>
            <p className="font-source-sans-pro">
                9c: Making meaningful improvements through technological
                changes.
            </p>
            <p className="font-source-sans-pro">
                9d: Using technology to achieve the same performance, but in
                a meaningfully better way.
            </p>
        </div>
    </Grid>

)